

ANNUAL REPORT 2002

National Foundation for Cancer Research

Research for a Cure

MISSION

The National Foundation for Cancer Research (NFCR) was founded in 1973 to support cancer research in the laboratory. NFCR research, conducted at both the cellular and molecular levels, is leading to better prevention, earlier diagnosis, new treatments and eventually a cure for cancer. By supporting the best ideas of the best minds and by facilitating collaboration among NFCR Project Directors, advances in one field contribute to discoveries in another. This is what NFCR's "Laboratory Without Walls" makes possible.

TABLE OF CONTENTS

Cover

Curt I. Civen, M.D.

Johns Hopkins University

NFCR Project Director

PRESIDENT'S MESSAGE

Franklin C. Salisbury, Jr.
President and CEO, NFCR

I am pleased to present to you the 2002 Annual Report for the National Foundation for Cancer Research (NFCR).

2002 was a difficult year for NFCR. But like so many Americans who were faced with challenges, NFCR – despite a weak economy and a corresponding downturn in charitable giving – overcame adversity and was able to continue its support of basic science cancer research. In addition to meeting our ongoing commitments, NFCR also embarked on a bold new initiative to help translate the discoveries being made by NFCR scientists in their laboratories to patients suffering from cancer.

Understanding molecular events is essential for developing effective treatments for cancer. Since 1973 NFCR has spent about $200 million in support of basic science cancer research and cancer prevention. For the last thirty years NFCR has been committed to supporting basic science research in the laboratory to unravel the molecular events causing cancer.

NFCR continues to lead in the war against cancer, and now that scientists have discovered how and where cancers start, NFCR is expanding our funding to include translational research. This will allow NFCR to influence all aspects of cancer research from the laboratory to a patient's bedside. After 30 years of funding basic science cancer research, we are at the dawn of a new era of diagnosing and treating cancer. Gene therapy, immunotherapy, and new drug discovery technologies bring with them new promises for curing cancer.

NFCR is prepared to help make real these promises of new treatments, diagnostic techniques, and even a cure for cancer. Still, much work needs to be done before these advances can be available to patients suffering from cancer. Years of hard work lie before us, and NFCR remains committed to funding scientists who are solving cancer's molecular mysteries and translating these discoveries into therapies that hold the only real hope for curing cancer. NFCR is *Research for a Cure.*

Sincerely,

Franklin Salisbury, Jr.
President
National Foundation for Cancer Research

OVERVIEW

Funding Breakthroughs

NFCR has provided the seed money for many of today's most promising breakthroughs in the prevention, diagnosis and treatment of all types of cancer. We are accelerating the pace of cancer research by recognizing innovative ideas at their infancy and providing scientists with the funding to initiate research.

Creating A Global Network Of Research Centers

NFCR has established an international network of research centers to create a "Laboratory Without Walls" that promotes the sharing of ideas and information across institutions and disciplines. Through this network, scientists at each NFCR center are focused on specific areas of research but are able to draw on expertise from other researchers with diverse specialties. This combination of focused science and expansive resources ensures a cure will be found more quickly.

NFCR Research Discovery Programs

Historically, NFCR has supported discovery-oriented basic science cancer research. Today, we're expanding into areas of translational and clinical research. By broadening our traditional research objectives, NFCR is now able to influence all areas of cancer research including drug discovery and the development of new therapies and better diagnostic techniques.



NFCR RESEARCH DISCOVERY PROGRAMS

NFCR is accelerating the pace of cancer research by recognizing innovative ideas in their infancy and providing scientists with the initial funding to substantiate their ideas. In order to maximize the productivity of its cancer research programs, NFCR has established an international network of research centers to create our "Laboratory Without Walls" that promotes the sharing of ideas and information across research institutions and a wide range of scientific disciplines.

Each of these centers is supported by several satellite laboratories. Led by NFCR Fellows and Project Directors, these centers focus on important and specific areas of cancer research. Through this network, NFCR supported scientists are able to collaborate and draw on expertise from other researchers. This synergistic collaboration greatly accelerates the progress in cancer research. Today, eight NFCR Research Centers have been established in addition to 30+ affiliated individual laboratories.

The Research Discovery Centers are listed below:

- NFCR Center for Genomics and Nutrition
- NFCR Center for Metastatic Cancer Research
- NFCR Center for New Therapies Development
- NFCR Center for Computational Drug Design
- NFCR Center for Protein and Nucleic Acid Chemistry
- NFCR Center for Molecular Analysis and Imaging
- NFCR Center for RNA Cancer Research
- NFCR Center for Molecular Oncology

NFCR Center for Genomics and Nutrition

University of California at Berkeley/Children's Hospital Oakland Research Institute

Under the direction of Drs. Bruce Ames and Martyn Smith, research at the Berkeley center is focusing on how proper nutrition can prevent cancer from developing in children as well as in adults. The NFCR Center for Genomics and Nutrition at Berkeley zeros in on the specific factors in diet that contribute to increased cancer risk. They are also working to identify the biochemical pathways by which nutrients, such as folic acid and vitamins B6 and B12 can protect individuals against cancer. By improving nutritional intake, it is estimated that 20 to 30 percent of all cases of cancer in the United States could be prevented. NFCR's Center for Genomics and Nutrition will further our understanding on the interactions and relationship between dietary factors and the prevention of cancer.

NFCR Center for Metastatic Cancer Research

University of Alabama/Penn State University/University of Chicago

Metastasis, or the spread of cancer cells, is the most lethal attribute of malignancy. Both breast and prostate cancers can be treatable when detected at an early stage, but become fatal when cancerous cells metastasize to the bone. Dr. Danny Welch and his team have been committed to understanding the problem of cancer metastasis for more than a decade. In addition to the twelve metastasis suppressor

genes identified (including the well-known breast/melanoma metastasis suppressor genes BRMS1 and KiSS1), Dr. Welch recently discovered DRIP130, a regulator gene of multiple metastasis suppressors. This finding offers a very promising target for designing future metastasis prevention /inhibition therapies.

NFCR Center for New Therapies Development

Arizona Cancer Center, University of Arizona

A key focus at this center is to find a cure for pancreatic cancer, one of the most deadly of all cancers. Drs. Daniel Von Hoff and Laurence Hurley, co-directors of the Arizona Cancer Center, are searching for what they call the "penicillin for cancer." In 2002, Drs. Von Hoff and Hurley found two potential new targets for treating pancreatic cancer, the urokinase-type plasminogen activator (uPA), and its receptor (uPAR). uPA is thought to play a central role in regulating proteolysis-related genes associated with the degradation of basement membranes and the extracellular matrix, which are major steps in many types of tumor progression and metastasis. With funding and support from NFCR, Drs. Von Hoff and Hurley are beginning clinical trials on several new drugs, one of which may very well be the "penicillin" we are searching for.

NFCR Center for Computational Drug Design

Univ. of Oxford, Oxford, UK/Univ. of Essex, Colchester, UK/Univ. of Alcala, Madrid, Spain
Univ. of Modena & Reggio Emilia, Modena, Italy/Univ. of Porto, Portugal

Since its inception in April 2001, NFCR's Screensaver-Lifesaver project has already provided more than 200,000 years of CPU time, and via virtual screening, yielded over 100,000 molecules, each with the potential of becoming anticancer drugs. Directed by University of Oxford Professor Graham Richards, our next step in capitalizing on this great success is to upgrade the system to the more sophisticated LIGANDFIT software, a drug discovery software program that calculates the 3-dimensional shapes of molecules. With increasing participation from the public, the computing capacity is expected to expand significantly in the future. The unprecedented efficiency of this new technology allows researchers to rapidly obtain a more diverse, complex, and complete scope of different drug-protein interactions, and thereby opens up a new horizon for future drug discovery.

NFCR Center for Protein and Nucleic Acid Chemistry

Yale University

Protein-RNA motifs play a key role in a variety of cellular processes including transcription, translation, and RNA processing. Co-directed by professors Dr. Alanna Schepartz and Dr. Don Crothers, NFCR's Center for Protein Chemistry at Yale was established to analyze the conformations, structures, and interaction kinetics of proteins and nucleic acids critical to the development of cancer. This is accomplished by disrupting the essential RNA-protein interactions with designed, sequence-specific RNA binding molecules. This research is providing further insight into how abnormalities of

proteins can lead to cancer. It is our belief that this approach will constitute a new generation of anticancer therapies; moving us from the systemic poisons represented by current chemotherapeutics to highly specific agents that target malignant cells with high specificity.

NFCR Center for Molecular Analysis and Imaging

Massachusetts General Hospital

The NFCR Center for Molecular Analysis and Imaging (NFCR-CMAI), co-directed by Harvard Medical School professors Drs. Ralph Weissleder and James Basilion, was established to enhance current imaging technologies so that non-invasive (no biopsy needed), "real-time" data can be provided to scientists and offer them important information about the formation of tumor cells. With more advanced imaging technology, scientists will be able to identify changes in gene expression that are specific to a particular cancer type, and indicate the possible presence of malignancy even before cells undergo transformation. Obtaining this knowledge will allow earlier treatments, as well as enabling patients to receive the most accurate diagnosis by identifying the specific nature of the cancers.

NFCR Center for RNA Cancer Research

Freie Universität, Berlin, Germany

RNA produces protein molecules critical for the survival of a cell. If the production of proteins with abnormal function can be inhibited, a tumor cell will not be able to survive. Directed by Dr. Volker A. Erdmann, an international leader and pioneer in the field of RNA research, NFCR's Center for RNA Cancer Research in Berlin focuses on developing an innovative "micro surgery method" that can be utilized to eliminate mRNAs crucial in the progression of cell transformation. Molecules currently under evaluation for their mRNA targets cleaving efficiency include synthetic DNAzymes, ribozymes, and interference RNAs (iRNAs). This method will accelerate the development of new sets of anticancer therapeutics.

NFCR Center for Molecular Oncology

Institute of Medicinal Biotechnology, Beijing, China

Cancerous cells can be characterized as cells reaching a state of uncontrolled growth. Under normal circumstances, cells undergo four different stages with several checkpoints that restrain them from dividing uncontrollably. In cancer cells, however, it is understood that these checkpoints have lost their regulatory function either partially or completely. Founded in 1997, NFCR's Center for Molecular Oncology is located in the Institute of Medicinal Biotechnology (IMB), Beijing, China. Directed by Dr. Jian-Dong Jiang, this center combines bioinformatic technology with traditional Chinese herbal remedies, and researchers here are exploring new generations of anticancer drugs by studying cell cycle regulatory mechanisms.

SPOTLIGHT ON NFCR SCIENTISTS

Dr. Susan Band Horwitz, at the Albert Einstein College of Medicine, is committed to understanding and solving the problem of tumor cell multidrug resistance. Focusing on novel anticancer drugs that maintain sufficient toxicity in Taxol-resistant tumor cells, two natural products, the epothilones and discodermolide, are under intensive study. Analogues of epothilones are currently in phase I and II clinical trails. The availability of such drugs could greatly benefit patients who have malignancies that did not respond to Taxol, or that originally responded yet developed resistance.

Dr. Yung-Chi Cheng, at Yale University, is conducting research on combining a Chinese herbal medicine formula (PHY906), a chemotherapy modulator, with currently available drugs such as CPT-11 and 5-FU to treat colorectal and lung cancer. Dr. Cheng has shown that PHY906 can reduce the toxicities of CPT-11 and 5-FU while enhancing their anti-tumor activities in treating colorectal and lung cancer. This research opens the door to a new paradigm in cancer medicine. Phase I/II clinical trials of PHY906 have been initiated for treatment of colorectal cancer.

Dr. Webster Cavenee is the Director of Ludwig Institute for Cancer Research. His work explores the regulation of the chromosome translocator FKHR gene family, and how its activities impact the development of cancer cells. Chromosome translocation refers to the displacement of genetic material from the original position to an alternative position. This phenomenon results in the re-assortment of a chromosome's coding sequence, and thereby leads to the production of abnormal proteins, eventually giving rise to cancer. To gain more complete understanding of these cancer-inducing events, Dr. Cavenee is currently working on identifying the targets and regulators of these genes, as well as how other genes within this family influence the cellular transformation process.

Dr. Phyllis Bowen, professor at University of Illinois at Chicago, is working on increasing self-induced cell death in prostate tissues. Dr. Helmut Sies, NFCR Fellow, professor of Heinrich-Heine Universität in Germany, is trying to understand how dietary intake of micronutrients and vitamins prevents DNA damage. These two seemingly unrelated projects are connected by one very important link – knowledge about lycopene. A pigment responsible for giving tomatoes their color, lycopene demonstrated a protective property against prostate and other types of cancer. Dr. Bowen is currently conducting in vivo studies to further explore the role of lycopene in the modification of DNA damage, programmed cell death, and cellular proliferation. Dr. Sies, on the other hand, continues to investigate other classes of molecules that may be crucial in the prevention of cellular oxidative damage.

Webster Cavenee, Ph.D.
Ludwig Institute for Cancer Research
NFCR Project Director

Susan B. Horwitz, Ph.D.
Albert Einstein College of Medicine
NFCR Project Director



Yung-Chi Cheng, Ph.D.
Yale University School of Medicine
NFCR Fellow

Planning Tip:

If you're planning to make a gift to NFCR, consider donating appreciated stocks. You will save yourself the capital gains taxes and receive a larger charitable tax deduction.

NFCR RESEARCHERS FUNDED IN 2002

NFCR Research Discovery Centers

NFCR Center for Genomics and Nutrition
University of California, Berkeley/Children's Hospital Oakland Research Center
Bruce N. Ames, Ph.D. Martyn T. Smith, Ph.D.
Nina T. Holland, Ph.D. Mark K. Shigenaga, Ph.D.

NFCR Center for Computational Drug Discovery
Univ. of Oxford, Oxford, UK/Univ. of Essex, Colchester, UK/Univ. of Alcala, Madrid, Spain/Univ. of Modena & Reggio Emilia, Modena, Italy/Univ. of Porto, Porto, Portugal
W. Graham Richards, D.Sc. Federico Gago, Ph.D.
M. Christina Menziani, Ph.D. Maria J. Ramos, Ph.D.
Christopher, A. Reynolds, Ph.D.

NFCR Center for New Therapies Development
Arizona Cancer Center, Tucson, Arizona
Daniel D. Von Hoff, M.D Laurence Hurley, Ph.D.

NFCR Center for Metastatic Cancer Research
Penn State Univ./Univ. of Chicago/Univ.of Alabama
Danny R. Welch, Ph.D. Andrea M. Mastro, Ph.D.
Carol V. Gay, Ph.D. Henry J. Donahue, Ph.D.
Carrie W. Rinker-Schaeffer, Ph.D.

NFCR Center for RNA Cancer Research
Freie Universität, Berlin, Germany
Volker A. Erdmann, Ph.D.
Rolfe Bald, Ph.D.
Jens Peter Fürste, Ph.D.

NFCR Center for Protein and Nucleic Acid Chemistry
Yale University, New Haven, Connecticut
Alanna Schepartz, Ph.D.
Donald M. Crothers, Ph.D.

NFCR Center for Molecular Analysis and Imaging
Massachusetts General Hospital, Boston, Massachusetts
Ralph Weissleder, M.D., Ph.D.
James P. Basilion, Ph.D.

NFCR Center for Molecular Oncology
Institute of Medicinal Biotechnology, Beijing, China
Jian-Dong Jiang, M.D., Ph.D.
Yong-Su Zhen, Ph.D.
Rong-Guang Shao, Ph.D.

NFCR Fellows

Yung-Chi Cheng, Ph.D.
Yale University School of Medicine
Exploration of Chinese medicine in relieving side effects and increasing therapeutic value of conventional chemotherapy.

Harold Dvorak, M.D.
Beth Israel Deaconess Medical Center
Elucidating the steps and mechanisms of tumor angiogenesis and contrasting these with the steps and mechanisms by which normal blood vessels form.

Alanna Schepartz, Ph.D.
Yale University
Director, NFCR Center for
Protein and Nucleic Acid Chemistry



Daniel D. Von Hoff, M.D.
Director, Arizona Cancer Center
Director, NFCR Center for
New Therapies Development

Danny R. Welch, Ph.D.
University of Alabama
Director, NFCR Center for
Metastatic Cancer Research

Waun Ki Hong, M.D.
MD Anderson Medical Center
Studying the effect of dietary folate and vitamin A in preventing lung cancer in women; Gleevec entering phase I clinical trial for treating small cell lung cancer.

Paul Schimmel, Ph.D
The Scripps Institute of Technology
Understanding aminoacyle tRNA synthetase and its promising role in inhibiting angiogenesis as well as controlling opportunistic infection resulting from chemotherapy.

I. Bernard Weinstein, M.D.
Columbia-Presbyterian Medical Center
Revealing abnormalities in the internal circuitry of cancer cells that are responsible for their abnormal proliferation and growth, and utilizing this knowledge to develop novel and more effective agents for both cancer prevention and therapy.

Helmut Sies, M.D.
Heinrich-Heine Universität
Addressing the underlying mechanism and biological impact of DNA damage related to ultraviolet radiation that give rise to skin cancer, and the defense systems repairing such damage.

NFCR Project Directors

Jacqueline K. Barton, Ph.D.
California Institute of Technology
Chemical studies of how oxidative damage to DNA can occur from a distance through DNA-mediated charge transport.

Robert Bast, Jr., M.D.
MD Anderson Cancer Center
Identifying novel tumor suppressor genes in epithelial ovarian cancer.

Stephen J. Benkovic, Ph.D.
Pennsylvania State University
Understanding how DNA that is replicated through replisome-protein complex at times falters in its operation leading to cancerous transformation of the cell.

Phyllis E. Bowen, Ph.D.
University of Illinois at Chicago
Researching the impacts of lycopene modulation on men with prostate cancer or pre-malignant lesion.

Webster Cavenee, Ph.D.
Ludwig Institute for Cancer Research
Characterization of FKHR gene family, a possible master gene regulator of angiogenesis.

Esther Chang, Ph.D.
Georgetown University
Exploring chemosensitization of breast cancer cells by systemic delivery of anti-HER2 oligonucleotides.

Curt I. Civin, M.D.
Johns Hopkins University
Studying the mechanism of action of a human leukemia gene by employing models for leukemia development.

Stanley N. Cohen, M.D.
Stanford University School of Medicine
Using random homozygous knockout procedure, identify, isolate and characterize genes that affect carcinogenesis and metastasis.

Wayne Marasco, M.D., Ph.D.
Dana Farber Cancer Institute
NFCR Project Director





Ivar Giaever, Ph.D.
Rensselaer Polytechnic Institute
NFCR Project Director

Stanley N. Cohen, M.D.
Stanford University School of Medicine
NFCR Project Director



Kathryn B. Horwitz, Ph.D.
University of Colorado Health Science Center
NFCR Project Director



Helmut Sies, M.D.
Heinrich-Heine Universität, Germany
NFCR Fellow

Donald M. Engelman, Ph.D.
Yale University
Studying possible roles of membrane helix interactions in viral carcinogenesis.

Xiaolian Gao, Ph.D.
University of Houston
Accelerating drug discovery processes by using microarray as a preliminary step for NMR characterization of drug-DNA complexes.

Ivar Giaever, Ph.D.
Rensselaer Polytechnic Institute
Developing highly sensitive Electric Cell-substrate Impedance Sensing technique for monitoring cancer cell behavior in real time.

Kathryn B. Horwitz, Ph.D.
University of Colorado Health Science Center
By analyzing the specific genes, predicting how an individual tumor will respond to an antihormone treatment like tamoxifen.

Susan Band Horwitz, Ph.D.
Albert Einstein College of Medicine
Searching for natural products that are analogues of Taxol that circumvent the problem of tumor multi-drug resistance.

Rakesh K. Jain, Ph.D.
Massachusetts General Hospital
Improve the delivery of drug into solid tumor by characterizing the root etiology of elevated fluid pressure within tumor.

Janos Ladik, Ph.D.
University Erlangen-Nurnberg
Studying the effects of chemical carcinogens and radiations on the activation of oncogenes.

Wayne A. Marasco, M.D., Ph.D.
Dana Farber Cancer Institute
Understanding the mechanism of transformation of human lymphocytes by the HTLV-1 virus.

Lawrence J. Marnett, Ph.D.
Vanderbilt University Medical Center
Quantification of COX-2, a molecule expressed in high levels in cancerous tissue, for the detection of tumor and evaluation of chemotherapy.

Thomas C. Merigan, Ph.D.
Stanford University School of Medicine
Researching insertion mutation of HIV-1 protease gene and its initiating effect on cancer.

Terence H. Rabbitts, Ph.D.
MRC Laboratory of Molecular Biology
Exploring the role of chromosomal translocation in the development of leukemia and lymphoma.

Alexander Rich, M.D.
Massachusetts Institute of Technology
Exploring the role of RNA editing in brain tumor.

Harold A. Scheraga, Ph.D.
Cornell University
Determining the folding pathway and stability of enzymes involved in cancer: ribonuclease, angiogenin and its inhibitors.

Michael B. Sporn, M.D.
Dartmouth Medical School
Developing of new triterpenoids compounds for the prevention of cancer.

NFCR Awards

AACR-NFCR Professorship in Basic Cancer Research

2002-2003: Victoria Lundblad, Ph.D. Professor, Department of Molecular and Human Genetics, Baylor College of Medicine. For her work in the function of chromosome ends and the end-replicating enzyme, telomerase. Understanding how telomerase contributes to cellular proliferation will help to reveal the fundamental factors leading to genetic diseases.

2000-2001: Daniel Haber, M.D., Ph.D. Researcher at the Massachusetts General Hospital Cancer Center. For his study in characterizing tumor suppressor genes involved in Wilm's tumor, a pediatric kidney cancer, and its relationship to increased risk of breast cancer.

AACR-NFCR Career Development Award

2001-2002: Karen M. Frank, M.D., Ph.D. Assistant Professor, Department of Pathology, University of Chicago. For her proposal entitled "DNA Ligase IV and DNA Repair". Her study will characterize DNA ligase IV complex, a crucial component of DNA end-joining pathway, and will investigate the mechanisms of V(D)J recombination process essential for normal lymphocyte development.

1999-2000: Fang Liu, Ph.D. Assistant Professor in the Department of Chemical Biology, Laboratory for Cancer Research, Rutgers University. For her proposal entitled "Role of TGF-beta-Inducible Gene Resulation in Tumorigenesis". Her study investigates how a newly discovered set of proteins (designated as SMADs) are regulated, and utilize this knowledge to further our understanding of the role of TGF-beta in tumorigenesis and cancer prevention.

Planning Tip:

Provide for your family and NFCR. There are many creative ways to give that don't make the decision an "either-or". You'll be surprised to learn how we can help. Contact one of our Gift Planning Officers at 1-800-321-CURE.

PUBLIC EDUCATION

At the National Foundation For Cancer Research, our motivation and determination is fueled by the devastating effect cancer has on so many families. Sparing patients and their families the desperation and heartbreak caused by this terrible disease is our ultimate goal, and we choose to reach this goal through the only means possible – research in the laboratory. We also realize that until a cure is found, it is important to empower people to avoid cancer by providing information that enables them to recognize the early warning signs of cancer and make healthy lifestyle choices.

With over 1,500 Americans dying from cancer, and 3,500 new cases being diagnosed each day, the numbers are shocking. NFCR provides free publications to the public containing valuable information on the most up-to-date preventive measures, treatment options, and diagnostic tools made available both by NFCR's dedicated scientists as well as other doctors and researchers in the medical and scientific research community.

NFCR Website: http//www.NFCR.org

You can access our user friendly website to learn about the latest and most advanced cancer prevention, diagnosis, and treatment options. Available at the website are frequent updates on NFCR's special events, monthly cancer-fighting recipes, and our Screensaver-Lifesaver projects.

NFCR Monthly E-Newsletter:

Our free electronic newsletter is delivered to your email account and discusses the most up-to-date discoveries and activities of NFCR researchers. Included in the newsletter are useful reminders of cancer prevention steps. Register for our free newsletter at **http://www.NFCR.org**.

Planning Tip:

Gain by Giving – a charitable gift annuity can provide you with a lifetime income and a generous tax deduction. Best of all, it will make an immediate difference today for NFCR's research programs.

On Your Health Series:

These insightful guides provide common-sense ways you can reduce your risk of cancer. To obtain any of these materials, please call **1-800-321-CURE** or download them at **www.NFCR.org**. We also offer professionally designed *On Your Health* calendars with healthy and delicious recipes for a more balanced diet!

The six publications in NFCR's *On Your Health* series include: Choose Crucifers: The Vital Veggies, The Facts about Fat, Walk Your Way to Wellness, Seek Shade–Not Sun, Finding Fiber, and Weigh Less–Live Longer.

From NFCR's *On Your Health* Series:

- *What Causes Cancer? Genes Vs. Environment*
- *Cancer-Fighting Minerals*
- *How To Reduce Radon In Your Home?*
- *Finding Fiber*
- *Smoking: The Leading Cause of Preventable Deaths*
- *The Facts About Fat*
- *Tea: The Latest Weapon Against Cancer*
- *Weigh Less–Live Longer*
- *Choose Crucifers–The Vital Veggies*
- *Seek Shade–Not Sun*
- *Should You Be Worried About Dioxin?*
- *Walk Your Way to Wellness*
- *Vitamin Supplements: A Word Of Caution For Cancer Patients*
- *Cancer Online*

NFCR's Cancer FAQs:

Your frequently asked questions are answered in depth. Topics include cancers of the breast, lung, prostate, colon, ovaries, liver, kidney, bladder, uterus, testes, and skin. This series also includes guides that answer your questions about treatment options such as radiation and chemotherapy.

From *NFCR's Cancer FAQs*:

- *Bladder*
- *Breast*
- *Cervical*
- *Colon*
- *Esophageal*
- *Kidney*
- *Leukemia*
- *Liver*
- *Lung*
- *Lymphoma*
- *Ovarian*
- *Pancreatic*
- *Prostate*
- *Testicular*
- *Uterine*
- *Skin*
- *Radiation Therapy*
- *Chemotherapy*

NFCR's Cancer Chart:

Now available: a detailed list of 22 of the most common cancers, this chart contains information about each cancer's signs and symptoms, diagnostic aids, treatment options, risk factors and suggested prevention methods.

FUNDING FOR A CURE

Planning Makes the Difference

In order to succeed in finding a cure for all types of cancer, NFCR recognizes that planning and choosing the right strategies are crucial. We must make sure that we invest our research dollars wisely so we can make the biggest impact in the shortest amount of time.

NFCR relies on the support of caring individuals to fund our research initiatives. In order to plan our attack against cancer, it is critical that we have the means available to fund new and innovative research opportunities.

The most common way to contribute to NFCR's cancer research program is to give a gift of cash. You can mail a contribution or make a donation online at www.NFCR.org. NFCR gladly accepts most major credit cards. If you would like to make your gift in Honor or Memory of someone, we'd be happy to tell you how.

Have you ever wanted to have the power to make this disease go away forever?

By including NFCR in your financial and estate planning, you can realize benefits for yourself, your family and NFCR's research all at the same time! You can help bring an end to cancer without jeopardizing your financial security.

Depending on your philanthropic goals and financial situation, certain types of gifts may be better for you. NFCR can offer several suggestions about creative giving options such as:

- *Gifts that pay you an income for life*
- *Gifts that can convert land into cash*
- *Gifts that give you tax savings three ways*
- *Gifts that you can live in*
- *Gifts to create a lasting legacy*
- *Gifts that you can get back*

If you would like to plan to help NFCR defeat cancer, please call 1-800-321-CURE for more information.

Remember, although NFCR can recommend gift planning options, you should always consult your personal lawyer or financial planner before making any final decisions.

Taking the Next Step:

To find out more about the following types of gifts, please call us at 1-800-321-CURE:

Charitable Gift Annuities	Wills and Bequests
Real Estate	Charitable Remainder Trusts
Appreciated Securities	Life Insurance

FINANCIAL STATEMENTS

NFCR Independent Auditors' Report
Board of Directors
National Foundation for Cancer Research, Inc.:

We have audited the accompanying consolidated statements of financial position of the National Foundation for Cancer Research, Inc. and affiliates (the Foundation) as of September 30, 2002, and the related consolidated statements of activities and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. The prior year summarized comparative information has been derived from the Foundation's 2001 financial statements and, in our report dated November 21, 2001, we expressed an unqualified opinion on those financial statements.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the National Foundation for Cancer Research, Inc. and affiliates at September 30, 2002, and their changes in net assets and their cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Our audit was conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplementary information included in the schedule of functional expenses is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

KPMG LLP

December 12, 2002

NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.
Consolidated Statement of Financial Position
September 30, 2002 and 2001

Assets		2002	2001
Cash and cash equivalents	$	633,536	785,659
Accounts receivable		422,545	420,210
Contributions receivable (note 2b)		182,806	305,959
Prepaid expenses and other assets		136,351	260,096
Advances to researchers (note 7)		322,500	—
Furniture and equipment, net of accumulated depreciation (note 3)		217,771	163,708
Investments (note 4)		4,954,397	4,193,846
Amounts held in trust by others (note 5)		1,483,820	1,706,049
	$	8,353,726	7,835,527
Liabilities and Net Assets			
Liabilities:			
Accounts payable and other liabilities	$	490,120	1,621,607
Accrued salaries and vacation pay		53,859	135,543
Deferred revenue		9,590	20,120
		553,569	1,777,270
Net assets:			
Unrestricted:			
Designated for research (note 7)		3,420,561	2,683,434
Undesignated		2,334,923	1,448,774
		5,755,484	4,132,208
Temporarily restricted (note 6)		769,149	512,121
Permanently restricted (note 6)		1,275,524	1,413,928
		7,800,157	6,058,257
Commitments (notes 7, 9, and 11)			
	$	8,353,726	7,835,527

See accompanying notes to consolidated financial statements.

NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.
Consolidated Statement of Activities
Year ended September 30, 2002
(with comparative totals for 2001)

	2002				
	Unrestricted	Temporarily restricted	Permanently restricted	Total	2001 Total
Revenues, gains and other support:					
Public support	$ 10,769,237	490,852	—	11,260,089	14,873,375
Bequests	2,011,082	—	—	2,011,082	1,340,247
Noncash support (note 8)	2,298,345	—	—	2,298,345	4,726,933
Mailing list rentals	959,065	—	—	959,065	927,016
Net investment loss (note 4)	(22,589)	—	—	(22,589)	(661,543)
Change in value of split interest agreements	—	(83,824)	(138,404)	(222,228)	(179,267)
Other revenue	47,103	—	—	47,103	77,715
Net assets released from restriction (note 6)	150,000	(150,000)	—	—	—
Total revenues, gains, and other support	16,212,243	257,028	(138,404)	16,330,867	21,104,476
Expenses:					
Program services:					
Research (notes 7 and 8)	6,348,244	—	—	6,348,244	9,941,268
Public education and information (note 10)	4,691,393	—	—	4,691,393	7,470,470
Total program services	11,039,637	—	—	11,039,637	17,411,738
Supporting services:					
Fundraising (note 10)	2,948,930	—	—	2,948,930	4,742,134
Management and general	600,400	—	—	600,400	572,228
Total supporting services	3,549,330	—	—	3,549,330	5,314,362
Total expenses	14,588,967	—	—	14,588,967	22,726,100
Change in net assets	1,623,276	257,028	(138,404)	1,741,900	(1,621,624)
Net assets, beginning of year	4,132,208	512,121	1,413,928	6,058,257	7,679,881
Net assets, end of year	$ 5,755,484	769,149	1,275,524	7,800,157	6,058,257

See accompanying notes to consolidated financial statements.

NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.
Consolidated Statements of Cash Flows
Years ended September 30, 2002 and 2001

	2002	2001
Cash flows from operating activities:		
Change in net assets	$ 1,741,900	(1,621,624)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	55,956	43,875
Net loss on investments	272,464	990,036
Contribution of furniture	(40,000)	—
Net loss on disposal of furniture and equipment	—	11,642
Contributions restricted for long-term investment	—	(144,238)
Decrease (increase) in assets:		
Accounts receivable	(2,335)	(51,088)
Contributions receivable	123,153	58,824
Prepaid expenses and other assets	123,745	207,471
Advances to researchers	(322,500)	—
Amounts held in trust by others	222,229	35,029
Increase (decrease) in liabilities:		
Accounts payable and other liabilities	(1,131,487)	(375,526)
Accrued salaries and vacation pay	(81,684)	35,414
Deferred revenue	(10,530)	(7,326)
Net cash provided (used) by operating activities	950,911	(817,511)
Cash flows from investing activities:		
Purchase of investments	(8,569,570)	(7,535,355)
Proceeds from sale or maturities of investments	7,536,555	8,932,461
Purchase of fixed assets	(70,019)	(73,347)
Net cash provided (used) in investing activities	(1,103,034)	1,323,759
Cash flows from financing activities:		
Permanently restricted contribution	—	144,238
Net increase (decrease) in cash	(152,123)	650,486
Cash and cash equivalents, beginning of year	785,659	135,173
Cash and cash equivalents, end of year	$ 633,536	785,659

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

(1) The Organization

National Foundation for Cancer Research, Inc. (the Foundation) was incorporated in Massachusetts in 1973 "to support basic science cancer research projects including the theories of Dr. Albert Szent-Gyorgyi who discovered Vitamin C." The purposes of the Foundation are to conduct basic science cancer research and to provide educational information about cancer to the public. The Foundation has provided services and operated under the names "Cancer Research Laboratories Foundation, Inc." and "Cancer Research Coalition." Both of these entities were inactive during the years ended September 30, 2002 and 2001.

Fund for Inherited Disease Research, Inc. (FIDR) was incorporated in October 2000 as a tax exempt supporting organization to the Foundation. FIDR is devoted to furthering scientific research related to Von Willebrand's Disease, a life-threatening genetic abnormality which afflicts females, particularly adolescents. FIDR was in its start-up phase and not fully operational during the year ended September 30, 2001. Its activities have been consolidated with those of the Foundation for the year ended September 30, 2002. All significant intercompany transactions and accounts have been eliminated.

(2) Summary of Significant Accounting Policies

The financial statements of the Foundation have been prepared on the accrual basis of accounting.

(a) Basis of Presentation

Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Foundation and changes therein are classified and reported as follows:

Unrestricted net assets – Net assets that are not subject to donor-imposed stipulations.

Temporarily restricted net assets – Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Foundation and/or the passage of time.

Permanently restricted net assets – Net assets subject to donor-imposed stipulations that they be maintained permanently by the Foundation.

Revenues are reported as increases in unrestricted net assets unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of temporary restrictions on net assets (i.e., donor-stipulated purpose has been fulfilled and/or stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets.

(b) Contributions

Public support is recorded as revenue when contributions, which include unconditional promises to give (pledges), are received. The Foundation has adopted a policy of recording donor-restricted contributions as unrestricted revenue if the restrictions are met in the same reporting period as the gift is received. All contributions receivable at September 30, 2002 and 2001 are expected to be received in one year.

(c) Bequests

The Foundation is the beneficiary under various wills and trust agreements. The Foundation records such amounts when notified that the amounts have cleared probate.

(d) Cash and cash equivalents

Cash equivalents include amounts invested in an overnight sweep account.

NFCR 2002 Allocation of Funds



(e) Prepaid Expenses

Prepaid expenses consist primarily of unused postage purchased prior to September 30.

(f) Furniture and Equipment

Expenditures for furniture and equipment are capitalized at cost using a capitalization threshold of $500. Furniture and equipment are depreciated on the straight-line basis over the estimated useful lives of the assets of 5 to 10 years. Leasehold improvements are capitalized at cost and amortized on the straight-line basis over the remaining life of the lease.

(g) Investments

Investments, which are recorded at fair value, consist of corporate stocks and bonds, government securities with maturities greater than 90 days, and money market funds.

(h) Functional Allocation of Expenses

The costs of providing the programs and services are summarized on a functional basis in the accompanying financial statements. Accordingly, certain costs have been allocated between the programs and services benefited. Joint costs of informational materials or activities that include a fundraising appeal have been allocated between fundraising and public education expenses.

(i) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The Foundation is also required to make estimates and assumptions that affect reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.

(j) Income Taxes

The Foundation qualifies as a public charity under Section 509(a) of the Internal Revenue Code and is generally exempt from federal income tax under Section 501(c)(3), except on unrelated business income, if any. FIDR is a Type I supporting organization under Section 509(a)(3) of the Internal Revenue code and is generally exempt from federal income tax under Section 501(c)(3), except for unrelated business income, if any.

Planning Tip:

Leave a Legacy – What better way to make a difference in the world than to leave a legacy of curing cancer? Consider including NFCR in your will to make your mark on the world for a cause you believe in.

Suggested wording for a Bequest:

"I bequeath Ten Percent (10%) of the residue of my estate to the National Foundation for Cancer Research, a Massachusetts non-profit corporation located in Bethesda, MD."

(3) Furniture and Equipment

Furniture and equipment at September 30, 2002 and 2001 consisted of the following:

	2002	2001
Computer equipment	$ 199,378	186,245
Office furniture and equipment	245,984	149,098
Leasehold improvements	23,917	23,917
	469,279	359,260
Less accumulated depreciation	(251,508)	(195,552)
	$ 217,771	163,708

(4) Investments

Investments at September 30, 2002 and 2001 consisted of the following:

	2002	2001
Money market funds	$ 1,687,774	1,007,365
Corporate bonds	196,498	—
Government and agency securities	1,576,109	1,471,740
Common and preferred stocks	1,494,016	1,714,741
	$ 4,954,397	4,193,846

Investment loss for the years ended September 30, 2002 and 2001 consisted of the following:

	2002	2001
Interest and dividend income	$ 249,875	328,493
Net loss on investments	(272,464)	(990,036)
	$ (22,589)	(661,543)

Foundation investments are managed by Prudential Securities, BB&T and Merrill Lynch. The amount in money market funds are classified as investments because the funds are intended to be held for investment purposes.

(5) Amounts Held in Trust by Others

The Foundation is the beneficiary of several split-interest agreements, including irrevocable perpetual trusts and charitable remainder trusts, as described in Internal Revenue code Section 664. The Foundation does not exercise control over the trusts' assets, which are held and administered by third-party trustees.

Under the perpetual trusts, the donors established and funded a trust whereby the Foundation is the beneficiary of the income on the trust assets as earned in perpetuity with no restrictions on its use. Under the charitable remainder trusts the donors established and funded a trust whereby the Foundation receives income distributions from the trust and will receive a percentage of trust assets at the termination of the trust.

The perpetual trusts are stated at the fair value of the assets of the trust. Fair value at September 30, 2002 and 2001 was $1,255,524 and $1,393,929, respectively. The decrease in the beneficial interest in perpetual trusts for the years ended September 30, 2002 and 2001 was ($138,404) and ($181,919), respectively.

The Foundation's interest in charitable remainder trusts is stated at fair value, representing the estimated amount to be received at the termination of the trusts. The amount recorded at September 30, 2002 and 2001 was $228,296 and $312,120, respectively.

(6) Net Assets

Temporarily restricted net assets at September 30, 2002 and 2001 consist of split-interest agreements held by the Foundation, net assets of the Fund for Inherited Disease Research consisting of contributions restricted for certain types of cancer research, and other miscellaneous contributions restricted for specific types of cancer research.

Temporarily restricted net assets released from restriction for the year ended September 30, 2002 related to contributions spent for specific types of cancer research. There were no temporarily restricted net assets released from restriction for the year ended September 30, 2001.

Permanently restricted net assets consist of perpetual trusts and endowments for which the Foundation is named as a beneficiary. Investment income realized on the permanently restricted net assets balance of $1,275,524 and $1,413,928 as of September 30, 2002 and 2001, respectively, is unrestricted for use by the Foundation.

(7) Research Contracts

The Foundation enters into agreements with universities or other institutions to conduct scientific research on their premises, in accordance with policies established by the governing board of the Foundation. Under the terms of these agreements, the Foundation provides specific funds on an annual basis subject to routine performance requirements by the recipients of the contracts. Research contracts are expensed in the year the research is conducted. Support provided to researchers in advance of the actual conduct of research is reported as advances to researchers.

At September 30, 2002 and 2001, the board of directors has designated unrestricted net assets in order to fulfill contract commitments to universities and institutions for research amounting to $3,420,561 and $2,683,434, respectively.

(8) Noncash Support

University Support

Research contracts with universities and institutions typically cover much of the research costs; however, most institutions agree to donate certain materials, services, and the use of equipment. These donations, provided by the institutions, become a normal part of the research program and would ordinarily be costs incurred by the Foundation.

Control over these donated materials, services, and equipment is provided through on-location project directors, who are responsible to the Foundation for the research project at the institutions.

The effect of these donations is to allow the Foundation to expand the research that would otherwise be performed under the contract. The institutions provide the Foundation with a measurable basis in order to quantify the estimated fair value of the donated materials, services, and facilities.

Computer Processing Contribution

During the fiscal year ended September 30, 2002, the Foundation received a noncash grant in the amount of $1.2 million, based on the number of processing hours incurred by the grantor at the rate of $0.10 per processing hour. A similar noncash grant in the amount of $3.6 million was received in the fiscal year ended September 30, 2001.

The grants were for the use of distributed computing technology in virtual drug screening. By utilizing a network of personal computers worldwide, the distributive computing software is able to screen billions of molecules against eight proteins that have been proven to be relevant for cancer, HIV, and other diseases.

For the years ended September 30, 2002 and 2001, noncash support consisted of the following:

	2002	2001
University support	$ 1,058,345	1,126,933
Computer processing contribution	1,200,000	3,600,000
Furniture donation	40,000	—
	$ 2,298,345	4,726,933

(9) Retirement Plan

The Foundation has a defined contribution money purchase plan which covers all full-time employees with at least 1,000 hours of annual service. The Foundation contributes an amount equal to 12% of the participating employees' eligible salaries to the plan each year. For the years ended September 30, 2002 and 2001, retirement expense was approximately $93,000 and $99,000, respectively.

(10) Allocation of Joint Costs

For the years ended September 30, 2002 and 2001, the Foundation incurred joint costs of approximately $6,751,000 and $11,204,000, respectively, for informational materials and activities that included fundraising appeals which were allocated as follows:

	2002	2001
Research	$ —	10,000
Fundraising	2,674,000	4,553,000
Public education and information	4,077,000	6,639,000
Management and general	—	2,000
	$ 6,751,000	11,204,000

(11) Lease Commitments

The Foundation and affiliates lease office space under a noncancelable operating lease. Future minimum lease payments under the operating lease as of September 30, 2002 are as follows:

2003	$ 163,432
2004	128,739
2005	132,599
2006	114,730
	$ 539,500

Rent expense for the years ended September 30, 2002 and 2001 was $152,398 and $107,201, respectively.

NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.
Consolidated Schedule of Functional Expenses
Year ended September 30, 2002
(with comparative totals for 2001)

Description	Research	Public education and information	Fundraising	Management and general	Total 2002	Total 2001
Conferences	$ 40,471	—	—	—	40,471	53,977
Creative fees	—	39,300	19,049	430	58,779	83,271
Data services	10,305	516,839	320,074	8,633	855,851	1,152,674
Depreciation	19,909	15,522	5,628	10,651	51,710	43,875
Dues and subscriptions	7,274	—	—	14,337	21,611	23,439
Fund for Inherited Disease Research	472,870	—	—	—	472,870	—
Investment fees	—	—	—	30,072	30,072	32,200
Legal fees	1,019	—	2,960	85,109	89,088	42,776
Licenses and permits	500	—	—	13,034	13,534	10,495
List processing fee	—	81,947	53,826	—	135,773	148,173
List rental	—	275,585	168,191	—	443,776	1,217,331
Lockbox and data entry	—	123,820	81,742	—	205,562	280,870
Mailshop fees	—	269,311	156,966	—	426,277	705,032
Miscellaneous	12,641	6,317	6,752	59,711	85,421	95,478
Noncash research support	2,258,345	—	—	—	2,258,345	4,726,933
Occupancy	40,143	32,810	12,211	22,345	107,509	107,201
Office supplies and expenses	14,094	12,979	5,026	11,277	43,376	44,168
Personnel	493,910	401,209	149,656	274,121	1,318,896	1,167,042
Postage	857	1,563,464	940,843	1,976	2,507,140	3,731,307
Printing and publication	2,009	1,027,019	786,544	—	1,815,572	3,390,169
Production fee	—	84,274	77,488	—	161,762	389,544
Professional fees	—	105,801	155,235	52,260	313,296	212,793
Public education materials and Web site	95,464	127,206	1,159	—	223,829	586,713
Research contracts and grants	2,828,423	—	—	—	2,828,423	4,401,408
Telephone	8,860	6,756	2,531	4,632	22,779	20,935
Travel and business meetings	41,150	1,234	3,049	11,812	57,245	58,296
	$ 6,348,244	4,691,391	2,948,932	600,400	14,588,965	22,726,100

See accompanying independent auditors' report.

ACKNOWLEDGEMENT OF CONTRIBUTORS

Imagine A World Without Cancer

Believing in the value of innovative research, NFCR is committed to supporting discovery-oriented research of proven scientists. Receiving no government funding, support from caring individuals like you is the primary means by which we enable our scientists to make significant breakthroughs in the war against cancer. Through an efficient organizational infrastructure, NFCR has provided many scientists with the "seed" money to explore and discover uncharted territories, and to bring these findings from laboratories to the bedside of cancer patients. Over the past 30 years NFCR has spent about $200 million to support innovative basic science cancer research and cancer prevention.

In fiscal year 2002, as always, NFCR and our scientists are immensely grateful to all our donors who have joined us in the fight against cancer. We extend our special appreciation to members who have generously contributed $1,000 or more. With your dedication and our determination, we will find a cure for cancer. NFCR is *Research for a Cure.*

Individuals

Amina R. Allaudin, M.D., PA
Mr. David Altman
Mr. & Mrs. Mark R. Angarola
Mr. Michael F. G. Ashby
Ms. Gertrude J. Bailey
Mr. Roger Baker
Mr. & Mrs. Dennis Barsema
Mrs. Thomas Bastis
Mr. & Mrs. Christian Beaumont
Mr. Frankie Beverly
Mrs. Jean A. Bogar
Ms. Helen C. Bones
Mr. William F. Borland
Ms. Lori A. Brotherton
David & Carol Buckel
Mr. Henry Buttery
Marvin & Yanka Cantor
Ms. Marilyn A. Carter
Miss Lila M. Challis
Mr. Alfred Chamizo
Dr. David K. G. Chan
Mr. & Mrs. Robert A. Christopher
Mrs. Alice B. Clark
Bruce & Wilma Classon
Mr. Scott E. Coleridge
Ms. Wendy Compton
Kevin & Diane Connolly
Ms. Carol L. Cook
Mr. David Y. Cooper
Ms. Joyce E. Cordon
Mr. E. Gerald Corrigan
John & June Crabb
Jan & Ken Creasman
Mr. Maurizio Croce
Mark Cuban
Ms. Joyce E. Dakis
Mr. Thomas C. Davey
Menahem & Linnea Deitcher
Ms. Doris J. Deuser
Thomas & Jennifer Dudley
Ms. Catherine W. Dukehart
Mrs. Betty A. Eberle
Dr. Richard P. Elinson
Mr. Richard D. Ennen
Mr. & Mrs. Edward R. Evans
Mr. & Mrs. Jeffrey Fang
Ms. Stephanie Fargo
Mr. Robert G. Finnigan
Walter & Gillian Fischer
David & Amber Flynn
Mr. Stephen H. Forbes
Ms. Hope E. Frungillo
Doris & Howard Garbo
Mr. & Mrs. James Gibson
Mr. & Mrs. Donald Gilmour
Mr. Robert B. Gordon
Carol & Arthur Graham
Mr. & Mrs. Kevin C. Green
Mr. Jay M. Grossman
Mr. Roderick V. Hamel
Mr. & Mrs. Michael Hamilton
Mr. David Hanisch
Mr. Robert T. Hanlon
Mrs. Virginia S. Henderson
Ms. Monika Henderson
Mr. & Mrs. Arthur Hiatt
Mr. Alvin Hill
Mr. Robert F. Hirsch
Ms. Carole B. Hogan
Ms. Sandra Horvath
Mr. & Mrs. David L. House
Ming Chu Hsu
Mr. & Mrs. A. Willard Ivers, Jr.
Mr. Jerry E. Jageman
Mr. Philip D. Jennison

Scott & Beatrice Johnson
Mrs. Martha Jones
Ms. LaVerne Kane
Lorie M. L. Karnath
Mr. N. Richard Kimmel
Mr. William B. King
Mr. Terry P. Kinskey
Ms. Martha J. Krauss
Ms. Donna Poljack Kurcz
Mr. Patrick H. Laing
Ms. Joyce L. Lander
Ms. Deborah A. Lange
Mr. Vito M. Lastella
Ms. Ann M. Layden
Ms. Cynthia H. Lee
Ms. Christine A. Leggio
Mr. Peter H. Lengemann
Mr. Harry J. Lewis
Mr. Michael J. Lichtman
Francis & Kathleen Lightly
Albert T. Linton
Robert & Mary Litterman
Mr. Leonard Litwin
Mr. Christopher Lloyd
Mr. & Mrs. Lee Loughnane
Mr. Brian J. Maas
Mr. Jack M. Machbitz
Mr. William G. Madary II
Mr. Leon Mandel III
Mr. Michael B. Mann
Mr. & Mrs. Martin Marlowe
John & Nancy Mauro
Ms. Joan McAndrew
Shawn & Jennifer McCreight
Ms. Laura L McDonald
Mr. Stephen E. McGrath
Mr. Thomas E. McGrath
Mr. Robert C. McIntyre
Jill & Gary Meltzger
Ms. Ruth P. Mills
Dr. Mario Molina
John & Janet Moore
Miss Elizabeth Moore Ruffin
Mr. & Mrs. Anthony R. Morgenthau
Ms. Jeannie A. Morris
Mrs. Ann Myers Williams
Mr. Carey S. Nachenberg
Ms. Beth Naughtin
Ms. Louise H. Neuhoff
Mr. William K. Nitterhouse
Mrs. Ruth H. O'Dea
Ms. Alice J. O'Donnell
Mr. Michael Olsen
Mr. R. David Orr
Ms. Terri Pallett
Mr. Girish Pande
Mr. Roland H. Parker
Mrs. Geraldine Parker
Mr. & Mrs. David Parker
Mr. & Mrs. James E. Perrella
Mr. & Mrs. Thomas C. Perry
Mr. Samuel L. Phillips
Davis Phoenix
Ms. Linda J. Pierret
Ms. Jennifer L. Reade
Mrs. Lora C. Redford
Mr. Jeffrey Richter
Mr. & Mrs. Craig Robinson
Mrs. Chong W. Robinson
Mr. & Mrs. C. Arthur Rolander, Jr.
Mr. & Mrs. Brent Rosenthal
Ms. Natalie Rotella
Mr. & Mrs. Michael Rothkopf
Mr. & Mrs Stephen Rudin
Mr. & Mrs. Anthony Rugnetta
Mr. & Mrs. John S. Sato
Mr. Roland Saunders, Jr.
Paul & Cleo Schimmel
Mr. Sheldon Schmertzler
Mr. Arthur A. Schwartz
Daniel & Elaine Scully
Mr. Rich Sharpenter
Mr. John D. Sheehy, Jr.
Mr. Mace Siegel
Ms. Catherine A. Sinkys
Joan & David Siskind
Ms. Marjory R. Smith
Mrs. Hope Noyes Smith
Mrs. Doreen C. Spitzer
Ms. Judy G. Sprinzen
Mrs. Susan B. Stearns
Mrs. Marie E. Steube

*In 1992, Vicky Love was diagnosed with a terribly painful type of cancer known as Chronic Lymphocytic Leukemia (CLL). Her boyfriend, **David Assmann**, was devastated. Wishing to spend more time with Vicky, David wanted to turn a valuable piece of real estate into a lifetime income without forfeiting a significant portion to taxes. NFCR helped David turn his land into cash through a Charitable Remainder Trust (CRT) and he received an income for life as well as generous charitable gift income tax deduction. Moreover, because of David, NFCR was able to establish a Research Endowment Fund.*

To the world, Lila Challis is an accomplished musician whose piano compositions have been performed by symphony orchestras. To NFCR, she is a loyal friend, making possible the research which will cure cancer. An example of what one person can do to touch the lives of thousands, Lila has shared the pride of our work with us for 14 years. She champions our persistent efforts in breaking down the barriers to understanding the molecular and genetic components of cancer, and continues her support for NFCR's Research for a Cure.

Individuals Continued...

Ms. Eleanor J. Stockwell
Mrs. Charlotte R. Strobl
Ms. Christianna L. Strohbeck
Mr. Mark Sullenberger
Mr. James R. Sullivan, Jr.
Ms. Josephine S. Sutland
Mrs. Florence R. Sutphen
Haruka Takano
Ms. Colette J. Tedeschi
Mr. & Mrs. Richard T. Thatcher
Mr. Richard M. Thomas
Ms. Yvonne Tolson
Mr. Wayne Tomfohrde
Ms. Pauline Tompkins
Mr. & Mrs. Emilio Torres Reyes
Mr.& Mrs. John M. Trani
Ms. Arline B. Turner
William & Jeanne Tyler
Mr. Daniel C. Vandermeulen
Daniel & Ann Von Hoff
Mrs. Joy A. Wallace
Mrs. Dorothy Wallgren
Mr. Mark J. Wasylenko
Mrs. Garnett R. Waterman
Mr. David L. Weck
Gary C. & Rosemarie Wendt
Ms. Allene M. White
Mr. & Mrs. Richard Withrow
Mr. & Mrs. Steve Wrench
Woody & Jeanette Wurster
Mr. Lee F. Wynn
Mr. & Mrs. Steve Zelko

Families, Foundations and Organizations

Altman Foundation
Mr. David Altman

LSI America Corporation
Dr. David K.G. Chan

Synthon Chirogenics
Mr. Scott E. Coleridge

The Corrigan Foundation
Mr. E. Gerald Corrigan

PROSTAFF
Corporational Intitiative

Bridgeway Capital Management
Ms. Monika Henderson

Robert & Mary Litterman Foundation
Robert & Mary Litterman

The Litwin Foundation, Inc.
Mr. Leonard Litwin

Pennsylvania Cancer Research Chapter
Ms. Joan McAndrew

Earth Atmospheric/Planetary Sciences
Dr. Mario Molina

Morgenthau Foundation
Mr. & Mrs. Anthony R. Morgenthau

Naughtin Family Foundation
Ms. Beth Naughtin

William J. Nitterhouse Charitable Fdn.
Mr. William K. Nitterhouse

Samuel L. Phillips Foundation
Mr. Samuel L. Phillips

The Rolander Family Foundation
Mr. & Mrs. C. Arthur Rolander, Jr.

Gifford-Rudin Foundation, Inc.
Mr. & Mrs. Stephen Rudin

The Wooster-Barcott Foundation
Mrs. Dorothy Wallgren

Abbott Laboratories Fund
Albert & Olive Schlink Foundation
Allied Domecq Retailing USA
Aon Foundation
Austin Lending, Incorporated
Blue Grass Foundation, Inc.
BP
BP Amoco Corporation
ConAgra Shared Purchasing, Inc.
Dickinson College
Dominion Foundation
Genta, Inc.
Heidrick & Struggels, Inc.
International Coffee Corporation
Ivins Phillips & Barker
John Wiley & Sons, Inc.
Johnson & Johnson
Joseph A. DeLuca, Inc.
Meyer & Esther Mazor Fdn., Inc.
Microsoft
Osceola Community Fund Drive
Sam's Club
Seat Pleasant Baptist Church
The Alvin & Fern Davis Fdn.
The Bellini Foundation
The Home Depot, USA
The JP Morgan Chase Foundation
Tennis for Tammy
TRICOM Marketing
TrizecHahn
TRW Employees Charity Org.
Vermeer Mid Atlantic, Inc.
Wiegand Family Foundation

Estate Gifts

Estate of Ellen T. Abbott
Estate of Mary S. Albren
Estate of Eleanor S. Bailey
Estate of Juliet S. Beveridge
Estate of Mary F. Borbeck
Estate of Sylvia F. Bowen
Estate of Warren J. Connor
Estate of Julius Eiermann
Estate if Isabelle I. Enyart
Estate of Henry T. Fleischhauer
Estate of Ruth C. Foley
Estate of Marie Elise Gatte
Estate of Edward J. Goldman
Estate of Thelma W. Haas
Estate of Louise J. Hewes
Estate of Frances A. Hollister
Estate of DeNard B. Kirk
Estate of Rose J. Mylott
Estate of William F. Nickel
Estate of Irene Pacanowski
Estate of Grace R. Phelps
Estate of Darcia Weiss
Estate of Henry Witte

Trust Gifts

Trust of Edna Archer Smith
Trust of Lucy Barnwell
Trust of Lucile G. Carlson
Trust of Marguerite Derx
Trust of Gertrude Dixon
Trust of Mildred R. Dumbauld
Trust of Wilbur C. Grosse
Trust of Leonard & Eustelle Hudson
Trust of Dora Kreuger
Trust of Dorsey T. Leard
Trust of Edward Low
Trust of Walter & Gusti Moellerich
Trust of Alfred & Eleanor Repecka
Trust of Mary M. Rugger
Trust of Eleanor Sentman
Trust of Owen S. Smith
Trust of Susan Mahn
Trust of Dorothy L. Woll
Trust of William R. & Lucilla S. Jackson
Trust of John T. Holowiak
Trust of Mary Anne Marcero

OFFICERS AND BOARD OF DIRECTORS

Officers

Franklin C. Salisbury, Jr., M.Div., J.D.

Tamara P. Salisbury

Sujuan Ba, Ph.D.

Board of Directors

G. Terry Sharrer, Ph.D.
Chairman of the Board

Stuart Cameron
Treasurer

Kevin Connolly

Lorie Karnath

Martha Sager, Ph.D.

Tamara P. Salisbury
Corporate Secretary

John V. Slye

4600 East West Highway
Suite 525
Bethesda, Maryland 20814
1-800-321-CURE
www.NFCR.org